CEBPG在卵巢癌中的表达及其临床意义  

The expression of CEBPG in ovarian cancer and its clinical significance

作　　者：张冬梅[1] 刘思佳 吴楠[1] 金焰[1] Zhang Dongmei;Liu Si;Wu Nan;Jin Yan(Laboratory of Medical Genetics,Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学医学遗传学研究室,150081 [2]哈尔滨医科大学附属第三医院妇科放疗科

出　　处：《国际遗传学杂志》2018年第4期231-240,共10页International Journal of Genetics

基　　金：国家自然科学基金（81371617）

摘　　要：目的 探讨卵巢癌中CCAAT增强子结合蛋白 γ（CCAAT enhancer binding protein gamma,CEBPG）基因的表达水平及临床意义.方法 免疫组织化学法检测卵巢癌组织芯片中92例卵巢癌和10例癌旁组织中CEBPG蛋白表达情况,并分析其表达与患者临床病理学参数的相关性;分别对Oncomine数据库中6个子集共540例和2个子集共186例卵巢癌患者的CEBPG mRNA表达和DNA扩增情况进行分析;对TCGA数据库中565例浆液性卵巢癌患者CEBPG表达水平与临床病理学参数及预后的相关性进行探讨;cBioPortal数据库分析CEBPG在浆液性卵巢癌组织中的基因改变情况和共表达相关基因,进一步通过DAVID数据库对CEBPG共表达基因（pearson相关系数〉0.2）富集分析,探讨其可能参与的信号通路.结果 组织芯片中CEBPG在卵巢癌中表达水平高于癌旁组织（P=0.004）,并且其在浆液性卵巢癌中表达高于非浆液性卵巢癌（P=0.049）;Oncomine和cBioPortal数据库中分析结果显示CEBPG在浆液性卵巢癌中mRNA表达和DNA扩增水平均增高;TCGA数据库数据分析表明CEBPG表达水平与浆液性卵巢癌患者分期呈负相关（2 vs 3,P=0.048;2 vs 4,P=0.009;3 vs4,P=0.018）,并且CEBPG高表达组患者的总体生存时间较低表达组短（P=0.032）,进一步的DAVID富集分析发现其可能参与细胞周期相关通路.结论 CEBPG 在卵巢癌特别是浆液性卵巢癌中明显高表达,且与浆液性卵巢癌患者分期和预后相关,其高表达可能通过调控细胞周期相关通路参与浆液性卵巢癌的发生发展, CEBPG 可能成为浆液性卵巢癌诊断和判断预后的分子标志物.Objective To explore the expression of CCAAT enhancer binding protein gamma （ CEBPG ） in ovarian cancer and its clinical significance . Methods Immunohistochemistry was used to detect the expression of CEBPG protein in 92 cases of ovarian cancer and 10 cases of non-tumor tissue in ovarian cancer tissue chip . The correlation between the expression of CEBPG protein and clinical data was analyzed . The Oncomine database was used to analyze CEBPG mRNA expression and DNA amplification levels in ovarian cancer . The TCGA database was used to analyze the correlation between CEBPG expres-sion and clinicopathological parameters and survival time of patients in 565 ovarian serous adenocarcinoma tissues . CEBPG gene alteration and co-expression gene were analyzed by cBioPortal database . An enrich-ment analysis of CEBPG co-expression genes （ Pearson correlation coefficient 〉0 . 2 ） based on cBioPortal database was performed using DAVID to investigate the signaling pathways . Results The expression of CEBPG protein in ovarian cancer tissues was higher than that in non-tumor tissues （ P =0 . 004 ） , and the expression of CEBPG in ovarian serous adenocarcinoma was higher than that in other types （ P =0 . 049 ） . The results from Oncomine and cBioPortal database showed that CEBPG mRNA expression and DNA amplification levels of CEBPG were high in ovarian serous adenocarcinoma; the expression of CEBPG was negatively correlated with stages （ Stage 2 vs Stage 3 , P =0 . 048; Stage 2 vs Stage 4 , P =0 . 009;Stage 3 vs Stage 4 , P =0 . 018 ） of ovarian serous adenocarcinoma patients in TCGA database; the overall survival time in patients with high CEBPG expression was shorter （ P = 0 . 032 ） . In addition , CEBPG may be involved in cell cycle progression revealed by DAVID database . Conclusion CEBPG is overex-pressed in ovarian cancer , especially in ovarian serous adenocarcinoma , and may involve the occurrence and development of ovarian serous adenocarcinoma and thus could be a biomarker of ovarian serous

关 键 词：卵巢癌 CEBPG 早期诊断 标志物 

分 类 号：R737.31[医药卫生—肿瘤]